Ignite Creation Date:
2025-12-24 @ 12:58 PM
Ignite Modification Date:
2026-02-22 @ 7:24 AM
Study NCT ID:
NCT00805961
Status:
COMPLETED
Last Update Posted:
2021-12-08
First Post:
2008-12-09
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM
Sponsor:
SCRI Development Innovations, LLC
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SCRI CNS 10
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None